Biogen (BIIB) Tax Provisions (2009 - 2026)
Biogen (BIIB) posted quarterly Tax Provisions of $34.9 million for Q2 2026, down 68.04% year-over-year from $109.2 million in Q2 2025, and down 40.03% quarter-over-quarter from $58.2 million in Q1 2026.
Biogen (BIIB) Tax Provisions (2009 - 2026) Analysis & Trends
Biogen's Tax Provisions history runs 18 years deep, the most recent figure standing at $34.9 million for Q2 2026.
- In Q2 2026, Tax Provisions fell 68.04% year-over-year to $34.9 million; the TTM figure through Jun 2026 stood at $176.8 million (down 33.83% YoY), while the FY2025 annual figure was $263.6 million, down 3.73% from the prior year.
- Tax Provisions for Q2 2026 stood at $34.9 million, down from $58.2 million in the prior quarter.
- The five-year high for Tax Provisions was $236.2 million in Q3 2022, with the low at -$72.9 million in Q3 2023.
- The 5-year median for Tax Provisions is $66.6 million (2024), against an average of $77.7 million.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions soared 1011.97% in 2022, then slumped 130.86% in 2023.
- Biogen's Tax Provisions stood at $54.3 million in 2022, then fell by 21.36% to $42.7 million in 2023, then plunged by 41.92% to $24.8 million in 2024, then tumbled by 128.63% to -$7.1 million in 2025, then surged by 591.55% to $34.9 million in 2026.
- Business Quant data shows BIIB's Tax Provisions at $34.9 million in Q2 2026, $58.2 million in Q1 2026, and -$7.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 34.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.90 Mn |
| Mar 31, 2026 | 58.20 Mn |
| Dec 31, 2025 | -7.10 Mn |
| Sep 30, 2025 | 90.80 Mn |
| Jun 30, 2025 | 109.20 Mn |
| Mar 31, 2025 | 70.70 Mn |
| Dec 31, 2024 | 24.80 Mn |
| Sep 30, 2024 | 62.50 Mn |
| Jun 30, 2024 | 115.10 Mn |
| Mar 31, 2024 | 71.40 Mn |
| Dec 31, 2023 | 42.70 Mn |
| Sep 30, 2023 | -72.90 Mn |
| Jun 30, 2023 | 114.80 Mn |
| Mar 31, 2023 | 50.70 Mn |
| Dec 31, 2022 | 54.30 Mn |
| Sep 30, 2022 | 236.20 Mn |
| Jun 30, 2022 | 216.70 Mn |
| Mar 31, 2022 | 125.60 Mn |
| Dec 31, 2021 | 443.20 Mn |
| Sep 30, 2021 | -25.90 Mn |